Skip to main content

Advertisement

Log in

Zolpidem (Ambien®) in pregnancy: placental passage and outcome

  • Original Contribution
  • Published:
Archives of Women's Mental Health Aims and scope Submit manuscript

Abstract

To examine the extent and clinical sequelae of fetal exposure to zolpidem, a commonly prescribed hypnotic agent. Pregnant women with psychiatric illness participating in a study of psychotropic pharmacokinetics were included. Zolpidem concentrations were analyzed in maternal and umbilical cord plasma collected at delivery. Outcomes were compared between the zolpidem-exposed group and a 1:1 matched comparator group. Forty-five women taking zolpidem during pregnancy were studied. Rates of preterm delivery and low birth weight were 26.7% and 15.6% respectively in the zolpidem-exposed group versus 13.3% and 4.4% in the matched comparator group, but no significant differences were found. The ratio of umbilical cord to maternal plasma zolpidem concentrations in 6 pairs ranged from 0.48 to 2.75. Zolpidem crosses the human placenta and rapidly clears the fetal circulation. Pregnant women with psychiatric illness treated with zolpidem may have less optimal obstetrical outcome, though it is unclear if this was related to the medication.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  • Askew J (2007) Zolpidem addiction in a pregnant women with a history of second-trimester bleeding. Pharmacotherapy 27(2):306–308

    Article  CAS  PubMed  Google Scholar 

  • Da Silva JB, Nakamura MU, Cordeiro JA, Kulay LJ (2005) Acupuncture for insomnia in pregnancy—a prospective, quasi-randomised, controlled study. Acupunct Med 23(2):47–51

    Article  PubMed  Google Scholar 

  • Field T, Hernandez-Reif M, Hart S, Theakston H, Schanberg S, Kuhn C (1999) Pregnant women benefit from massage therapy. J Psychosom Obstet Gynaecol 20(1):31–8

    Article  CAS  PubMed  Google Scholar 

  • Field T, Diego M, Hernandez-Reif M, Figueiredo B, Schanberg S, Kuhn C (2007) Sleep disturbances in depressed pregnant women and their newborns. Infant Behav Dev 30:127–133

    Article  PubMed  Google Scholar 

  • Franklin KA, Holmgren PA, Jonsson F, Poromaa N, Stenlund H, Svanborg E (2000) Snoring, pregnancy-induced hypertension, and growth retardation of the fetus. Chest 117:137–141

    Article  CAS  PubMed  Google Scholar 

  • Lee KA, Gay CL (2004) Sleep in late pregnancy predicts length of labor and type of delivery. Am J Obstet Gynecol 191:2041–2046

    Article  PubMed  Google Scholar 

  • Miller EH (2004) Women and insomnia. Clin Cornerstone 6(1B):S6–S18

    Article  Google Scholar 

  • Physicians Desk Reference (2009) (PDR 61st ed). Thomson, Montvale, pp 2692–2701

  • Skouteris H, Germano C, Wertheim EH, Paxton SJ, Milgrom J (2008) Sleep quality and depression during pregnancy: a prospective study. J Sleep Res 17(2):217–20

    Article  PubMed  Google Scholar 

  • Stowe ZN, Ragan K (2008) ACOG practice bulletin: clinical management guidelines for obstetrician-gynecologists. Bulletin number 92, April 2008. Use of psychiatric medications during pregnancy and lactation. Obstet Gynecol 111(4):1001–1020

    Google Scholar 

  • Wikner BN, Stiller CO, Bergman U, Asker C, Kallen B (2007) Use of benzodiazepines and benzodiazepine receptor agonists during pregnancy: neonatal outcome and congenital malformations. Pharmacoepidemiol Drug Saf 16:1203–1210

    Article  PubMed  Google Scholar 

  • Wilkie G, Shapiro CM (1992) Sleep deprivation and the postnatal blues. J Psychosom Res 36(4):309–16

    Article  CAS  PubMed  Google Scholar 

  • Wilton LV, Pearce GL, Martin RM, Mackay FJ, Mann RD (1998) The outcomes of pregnancy women exposed to newly marketed drugs in general practice in England. Br J Obstet Gynaecol 105:882–889

    CAS  PubMed  Google Scholar 

Download references

Acknowledgments

Supported by NIH grant MH-68036 (to ZNS).

Disclosures

Ms. Juric and Ms. Galanti have received salary support from NIH. Dr. Newport has received research support from Eli Lilly, GlaxoSmithKline (GSK), Janssen, and Wyeth as well as NARSAD and NIH, and speaker’s honoraria from Astra-Zeneca, Eli Lilly, GSK, and Pfizer. Dr. Ritchie has received research support from GSK and has served on advisory boards for CeNeRx Pharma, and Abaxis. Dr. Stowe has received research support from GSK, NIH, and Wyeth, served on advisory boards for Wyeth, BMS and GSK, and received speakers’ honoraria from Eli Lilly, GSK, Pfizer, and Wyeth.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Zachary N. Stowe.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Juric, S., Newport, D.J., Ritchie, J.C. et al. Zolpidem (Ambien®) in pregnancy: placental passage and outcome. Arch Womens Ment Health 12, 441–446 (2009). https://doi.org/10.1007/s00737-009-0100-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00737-009-0100-7

Keywords

Navigation